evidoria

← Back to browse

Good practice Imported

T3 — Technion Technology Transfer (Haifa)

Israel · Haifa · See the Israel profile

Evidence: Observational / pre–post Top 54% 67/100 · Ask Evidence Copilot about this practice

Run since 2005 by the Technion R&D Foundation, T3 has helped the Technion place among the world's top 100 patent-granted universities for 5 straight years (81st globally in 2025), spinning out medtech firms later bought by Medtronic, J&J and Siemens Healthineers.

68th global rank
US utility patent ranking (2022) (2022)
65th global rank
US utility patent ranking (2023) (2023)
81st global rank
US utility patent ranking (2025) (2025)
100 million USD (exceeding)
AMIT incubator philanthropic funding (cumulative donation)
T3 — Technion Technology Transfer (Haifa)

Details

Maturity
Established
Promoter
T3 — Technion Technology Transfer (Technion Research & Development Foundation)
Period
2005–present
Keywords
University technology transfer, medtech spin-offs, patent licensing

Context

T3 is the technology-transfer arm of the Technion Research & Development Foundation, operating since 2005 from Haifa, Israel, to commercialize intellectual property from the Technion – Israel Institute of Technology, led by attorney Benjamin Soffer with an 11-member team.

Objectives

T3 aims to evaluate and patent inventions, negotiate industry licenses, and run acceleration/incubation programs to convert Technion research into commercial ventures.

Activities

T3 operates AMIT, a medical-device incubator funded by a donation exceeding $100 million from philanthropist Alfred E. Mann, negotiates licenses, and has supported collaborations such as the development of the Parkinson's drug rasagiline (Azilect) with Teva Pharmaceuticals.

Results

Technion has ranked among the global top 100 institutions for US utility patents for five consecutive years (68th in 2022, 65th in 2023, 81st in 2025); notable T3-linked spin-offs include Mazor Robotics (acquired by Medtronic), Biosense (Johnson & Johnson), Corindus (Siemens Healthineers) and Pluristem Therapeutics.

Conclusions

T3 demonstrates a long-running, professionally managed university technology-transfer model with sustained patent output and multiple large acquisition exits, though patent counts alone do not indicate research quality and no equity/inclusion data is available.

Implementation
Indicative cost
Medium (€50k–€500k)
Time to results
Long (> 3 years) — Operating since 2005; sustained global top-100 US utility patent ranking for five consecutive years through 2025.
Staffing & skills
11-member team led by attorney Benjamin Soffer

Conditions for success

  • Dedicated professional legal/licensing staff (11-member team led by an attorney)
  • Large philanthropic funding for specialized incubators (AMIT, $100M+ donation from Alfred E. Mann)
  • Long-term industry partnerships for drug/device co-development (e.g., Teva Pharmaceuticals)

Common failure modes

  • Patent count rankings do not by themselves indicate research quality; equity/inclusion data unavailable

Where it fits

Governance type
university-affiliated technology-transfer foundation
Scale
institutional (single university)
Income level
high income (Israel)

Commonly funded by

Philanthropic / foundation funding

Indicative funding routes for practices of this type — always check each programme's current calls and eligibility rules.

Do you run this practice? Claim it — verified implementers get a public contact pathway and can propose corrections.

Data sources

Where this practice's information was retrieved from, and when.

Attachments

Similar practices you may find useful